AA
INSY

ALPS Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

ALPS Advisors’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-30,564
Closed -$281K – 875
2016
Q4 		$281K Buy
30,564
+289
+1% +$3.27K ﹤0.01% 674
2016
Q3 		$357K Buy
30,275
+7,826
+35% +$119K ﹤0.01% 630
2016
Q2 		$290K Sell
22,449
-1,648
-7% -$24K ﹤0.01% 582
2016
Q1 		$385K Buy
+24,097
New +$458K ﹤0.01% 568
2015
Q3 		– Sell
-17,887
Closed -$643K – 812
2015
Q2 		$643K Buy
17,887
+277
+2% +$8.63K 0.01% 258
2015
Q1 		$512K Sell
17,610
-13,254
-43% -$351K ﹤0.01% 536
2014
Q4 		$651K Sell
30,864
-4,336
-12% -$85.7K 0.01% 215
2014
Q3 		$683K Buy
+35,200
New +$553K 0.01% 184

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCP
Fine Capital Partners New York $563M AUM 7.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ALPS Advisors's INSY Position: Q1 2017 in Review

ALPS Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q1 2017, closing a stake of 30,564 shares — an estimated $281K sold.

ALPS Advisors first reported a position in INSY in Q3 2014 and held it in 8 quarters. The position peaked at $683K in Q3 2014. 116 funds tracked by Wall St. Rank hold INSY as of Q1 2017.

  • ALPS Advisors reported no remaining Insys Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • ALPS Advisors sold 30,564 Insys Therapeutics, Inc. shares in Q1 2017, an estimated $281K.
  • ALPS Advisors first reported a position in Insys Therapeutics, Inc. in Q3 2014 and held it in 8 quarters.
  • ALPS Advisors's Insys Therapeutics, Inc. position peaked at $683K in Q3 2014.
  • 116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2017.

Based on ALPS Advisors's 13F filing for Q1 2017, filed 12 May 2017.